https://www.selleckchem.com/products/ml323.html Everolimus is a mTOR inhibitor which demonstrates clinical activity in several solid tumors, especially in kidney cancer after first line TKI anti VEGF treatment and in breast cancer in association with exemesthane after failure of aroamatase inhibitors. The purpose of this study was to analyze in clinical practice the tolerance of everolimus in patients with breast cancer and kidney cancer. We conducted a retrospective study on patients followed up for breast cancer and kidney cancer over the period January 2008 - January 2015. All patients received everolimus at a dosage of 10 mg/day alone or in association with exemesthane for breast cancer. Adverse reactions were classified according to the National Cancer Institute Common Terminology Criteria for Adverses version 4.0 (NCI-CTCAE). A total of 100 patients were enrolled in the study 76 patients with breast cancer and 24 patients with kidney cancer. The median follow-up period was 5.7 months. Treatment was stopped in more than 70% of the cases because of intolerance. The main adverse events, with a prevalence of more than 30% for all grades were mucositis, rash, fatigue, anemia, lymphopenia, hyperglycaemia, hyperlipidemia and infections. Mucositis, noninfectious pneumopathies and infections had high incidence of toxicity grade 3-4. Treatment discontinuation rate due to intolerance is high compared to literature data. At the beginning of treatment, particular attention should be given to mucositis, the immunosuppressive effect of treatment and non-infectious pneumopathies. The loss of parenchymal brain volume per normative age comparison is a distinctive feature of brain atrophy. While the condition is the most prevalent to elderly, it has also been observed in pediatric ages. Various causes such as trauma, infection, and malnutrition have been reported to trigger the loss of brain tissues volume. Despite this literature based knowledge of risk factors, the magnitude o